NASDAQ:COLL

Collegium Pharmaceutical Stock Insider Trading

Healthcare > Drug Manufacturers - Specialty & Generic

Buy COLL

*Your capital is at risk

$31.06

+0.580 (+1.90%)

At Close: Jun 03, 2026

Collegium Pharmaceutical Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -64.76. In total, the insiders bought 860.21K and sold 468.05K COLL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-64.76
● Buy	860.21K shares
● Sell	468.05K shares
62% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Mar 03, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -64.76. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 18, 2026 Sell	Common Stock S-Sale	Freund John Gordon Director	Director	20 Value: $681
May 15, 2026 Sell	Common Stock S-Sale	Freund John Gordon Director	Director	4 127 Value: $142.5K
May 15, 2026 Buy	Common Stock M-Exempt	Freund John Gordon Director	Director	8 700 Value: $143.5K
May 15, 2026 Buy	Stock Option (Right to Purchase) M-Exempt	Freund John Gordon Director	Director	8 700 Value: $143.5K
May 14, 2026 Buy	Common Stock A-Award	Santini Gino Director	Director	8 741 Value: $304.4K
May 14, 2026 Buy	Common Stock A-Award	Balice-gordon Rita J. Director	Director	8 741 Value: $304.4K
May 14, 2026 Buy	Common Stock A-Award	Glancy Donovan Michael Director	Director	17 482 Value: $608.9K
May 14, 2026 Buy	Common Stock A-Award	Bohlin Garen G Director	Director	8 741 Value: $304.4K
May 14, 2026 Buy	Common Stock A-Award	Lurker Nancy Director	Director	8 741 Value: $304.4K
May 14, 2026 Buy	Common Stock A-Award	Paya Carlos V Director	Director	8 741 Value: $304.4K
May 14, 2026 Buy	Common Stock A-Award	Freund John Gordon Director	Director	8 741 Value: $304.4K
May 14, 2026 Buy	Common Stock J-Other	Glancy Donovan Michael Insider	Other	0 Value: $0
May 13, 2026 Sell	Common Stock S-Sale	Lurker Nancy Director	Director	4 500 Value: $161.9K
May 11, 2026 Buy	Stock Option (Right to Purchase) M-Exempt	Bohlin Garen G Director	Director	8 700 Value: $143.5K
May 11, 2026 Sell	Common Stock S-Sale	Bohlin Garen G Director	Director	8 700 Value: $323.5K
May 11, 2026 Buy	Common Stock M-Exempt	Bohlin Garen G Director	Director	8 700 Value: $143.5K
Mar 18, 2026 Sell	Common Stock S-Sale	Dieter David EVP & General Counsel	Officer	13 976 Value: $488.1K
Mar 17, 2026 Sell	Common Stock F-InKind	Dieter David EVP & General Counsel	Officer	8 840 Value: $315.8K
Mar 03, 2026 Sell	Common Stock S-Sale	Dreyer Scott EVP & Chief Commercial Officer	Officer	3 559 Value: $145.9K
Mar 03, 2026 Sell	Common Stock S-Sale	Dreyer Scott EVP & Chief Commercial Officer	Officer	46 417 Value: $1.87M
Feb 10, 2026 Sell	Common Stock F-InKind	Tupper Colleen EVP & Chief Financial Officer	C-Suite Officer	26 679 Value: $1.25M
Feb 10, 2026 Buy	Common Stock A-Award	Tupper Colleen EVP & Chief Financial Officer	C-Suite Officer	26 421 Value: $1.24M
Feb 10, 2026 Sell	Common Stock F-InKind	Tupper Colleen EVP & Chief Financial Officer	C-Suite Officer	11 861 Value: $554.5K
Feb 10, 2026 Buy	Common Stock A-Award	Tupper Colleen EVP & Chief Financial Officer	C-Suite Officer	32 734 Value: $1.53M
Feb 10, 2026 Sell	Common Stock F-InKind	Karnani Vikram President And CEO	CEO / President	11 296 Value: $528.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT COLLEGIUM PHARMACEUTICAL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatm...

Read Full Profile Here